Microbix Biosystems (TSX:MBX) ROCE % : 7.17% (As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Microbix Biosystems's annualized ROCE % for the quarter that ended in Mar. 2024 was 7.17%.

Microbix Biosystems ROCE % Historical Data

The historical data trend for Microbix Biosystems's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems ROCE % Chart

Microbix Biosystems Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROCE %

Get a 7-Day Free Trial

7.40

-27.32

27.53

9.95

2.59

Microbix Biosystems Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															3.17	-7.52	29.51	32.92	7.17

Microbix Biosystems ROCE % Calculation

Microbix Biosystems's annualized ROCE % for the fiscal year that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	0.8	/	( ( (33.145 - 2.651)	+	(35.653 - 4.35) )	/ 2 )
	=	0.8	/	( (30.494	+	31.303)	/ 2 )
	=	0.8	/	30.8985
	=	2.59 %

Microbix Biosystems's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	2.444	/	( ( (36.707 - 2.778)	+	(37.922 - 3.719) )	/ 2 )
	=	2.444	/	( ( 33.929	+	34.203 )	/ 2 )
	=	2.444	/	34.066
	=	7.17 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Microbix Biosystems (TSX:MBX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Microbix Biosystems ROCE % Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Microbix Biosystems (TSX:MBX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MBXBF:USA

Address

265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3

Website

https://www.microbix.com

Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.

Executives

James Stuart Currie

Senior Officer

Microbix Biosystems (TSX:MBX) Headlines

No Headlines